Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Lung Neoplasms 7Adenocarcinoma Of Esophagus 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Esophageal Neoplasms 2Adenocarcinoma 2Sarcoma 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Metastatic Gastric Adenocarcinoma 1Head and Neck Neoplasms 1Desmoplastic Small Round Cell Tumor 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Advanced Gastric or EGJ Cancer 1

Interventions

trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1Ramucirumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Gastric Adenocarcinoma × Ramucirumab × 90 days × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡